[Retracted] miR-100-5p Is a Novel Biomarker That Suppresses the Proliferation, Migration, and Invasion in Skin Cutaneous Melanoma

Table 1

The baseline clinical characteristics of TCGA-SKCM.

Characteristic	Levels	Low expression of hsa-miR-100-5p	High expression of hsa-miR-100-5p
Gender, (%)	Female	84 (18.7%)	88 (19.6%)	0.771
	Male	141 (31.3%)	137 (30.4%)
Age, (%)	≤60	109 (24.7%)	135 (30.5%)	0.013
	>60	113 (25.6%)	85 (19.2%)
T stage, (%)	T1	21 (6.1%)	17 (4.9%)	<0.001
	T2	31 (9%)	48 (13.9%)
	T3	35 (10.1%)	50 (14.5%)
	T4	93 (27%)	50 (14.5%)
N stage, (%)	N0	113 (28.3%)	113 (28.3%)	0.005
	N1	27 (6.8%)	43 (10.8%)
	N2	20 (5%)	29 (7.3%)
	N3	37 (9.3%)	17 (4.3%)
M stage, (%)	M0	197 (46.5%)	203 (47.9%)	0.513
	M1	14 (3.3%)	10 (2.4%)
Breslow depth, (%)	≤3	74 (21.6%)	106 (31%)	<0.001
	>3	100 (29.2%)	62 (18.1%)
Melanoma ulceration, (%)	No	66 (22.1%)	75 (25.1%)	0.008
	Yes	99 (33.1%)	59 (19.7%)
Melanoma Clark level, (%)	I	2 (0.7%)	4 (1.3%)	0.003
	II	9 (2.9%)	8 (2.6%)